Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-02-08

Clinical Trial Update: Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on cyclosporine for recurrent or refractory angioimmunoblastic T-cell lymphoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CYCLOSPORINE (cyclosporine)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2013-02-08